Kymera Therapeutics (KYMR) Depreciation and Depletion (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Depreciation and Depletion data on file, last reported at $1.6 million in Q1 2026.

• Depreciation and Depletion for Q1 2026 came in at $1.6 million, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.3 million (up 10.67% YoY), and the FY2025 annual result was $8.3 million, up 12.16% from the prior year.
• Depreciation and Depletion eased to $1.6 million in Q1 2026 per KYMR's latest filing, from $2.9 million in the prior quarter.
• Over five years, Depreciation and Depletion peaked at $2.9 million in Q4 2025 and troughed at $700000.0 in Q1 2022.
• A 5-year average of $1.4 million and a median of $1.5 million in 2024 frame the typical range for Depreciation and Depletion.
• On a YoY basis, Depreciation and Depletion climbed as much as 114185.71% in 2022 and fell as far as 66.64% in 2022.
• A 5-year view of Depreciation and Depletion shows it stood at $800000.0 in 2022, then grew by 12.5% to $900000.0 in 2023, then surged by 122.22% to $2.0 million in 2024, then jumped by 45.0% to $2.9 million in 2025, then tumbled by 44.83% to $1.6 million in 2026.
• Business Quant data shows KYMR's Depreciation and Depletion at $1.6 million in Q1 2026, $2.9 million in Q4 2025, and $2.1 million in Q3 2025.